JP2024501246A5 - - Google Patents
Info
- Publication number
- JP2024501246A5 JP2024501246A5 JP2023537946A JP2023537946A JP2024501246A5 JP 2024501246 A5 JP2024501246 A5 JP 2024501246A5 JP 2023537946 A JP2023537946 A JP 2023537946A JP 2023537946 A JP2023537946 A JP 2023537946A JP 2024501246 A5 JP2024501246 A5 JP 2024501246A5
- Authority
- JP
- Japan
- Prior art keywords
- chr16
- cells
- cell
- manipulated
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130098P | 2020-12-23 | 2020-12-23 | |
| US63/130,098 | 2020-12-23 | ||
| US202163251002P | 2021-09-30 | 2021-09-30 | |
| US63/251,002 | 2021-09-30 | ||
| US202163254971P | 2021-10-12 | 2021-10-12 | |
| US63/254,971 | 2021-10-12 | ||
| US202163288502P | 2021-12-10 | 2021-12-10 | |
| US63/288,502 | 2021-12-10 | ||
| PCT/US2021/064933 WO2022140587A1 (en) | 2020-12-23 | 2021-12-22 | Compositions and methods for genetically modifying ciita in a cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501246A JP2024501246A (ja) | 2024-01-11 |
| JP2024501246A5 true JP2024501246A5 (enExample) | 2025-09-02 |
Family
ID=80445732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537946A Pending JP2024501246A (ja) | 2020-12-23 | 2021-12-22 | 細胞中のｃｉｉｔａを遺伝子修飾するための組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240139323A1 (enExample) |
| EP (1) | EP4267723A1 (enExample) |
| JP (1) | JP2024501246A (enExample) |
| KR (1) | KR20230135068A (enExample) |
| AU (1) | AU2021410751A1 (enExample) |
| BR (1) | BR112023012432A2 (enExample) |
| CA (1) | CA3205042A1 (enExample) |
| CL (2) | CL2023001855A1 (enExample) |
| CO (1) | CO2023009613A2 (enExample) |
| CR (1) | CR20230321A (enExample) |
| IL (1) | IL303970A (enExample) |
| MX (1) | MX2023007465A (enExample) |
| TW (1) | TW202242101A (enExample) |
| WO (1) | WO2022140587A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116042676A (zh) * | 2023-01-04 | 2023-05-02 | 上海南方模式生物科技股份有限公司 | 一种基于CRISPR-Cas9构建TNF-α-HiBit动物模型的方法 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025038648A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049631A1 (en) * | 2023-08-28 | 2025-03-06 | Kyverna Therapeutics, Inc. | Allogeneic car-t cell therapies and manufacture thereof |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| EP0760008A1 (en) | 1994-05-19 | 1997-03-05 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| EP2997146A4 (en) * | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| EP3294342A4 (en) * | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| EP3551757A1 (en) | 2016-12-08 | 2019-10-16 | Intellia Therapeutics, Inc. | Modified guide rnas |
| JP7170666B2 (ja) | 2017-05-08 | 2022-11-14 | プレシジョン バイオサイエンシズ，インク． | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| BR112019023608A2 (pt) * | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| EP3688162B1 (en) | 2017-09-29 | 2024-03-06 | Intellia Therapeutics, Inc. | Formulations |
| AU2018383712B2 (en) * | 2017-12-11 | 2025-09-04 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| JP7832761B2 (ja) | 2018-06-08 | 2026-03-18 | インテリア セラピューティクス，インコーポレイテッド | 遺伝子編集のための修飾されたガイドｒｎａ |
| WO2019237035A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| CN113166743B (zh) | 2018-10-15 | 2026-04-07 | 马萨诸塞大学 | Nme2cas9-脱氨酶融合蛋白的可编程dna碱基编辑 |
| CA3116132A1 (en) | 2018-10-16 | 2020-04-23 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| US12600971B2 (en) * | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| SG11202108891QA (en) * | 2019-02-15 | 2021-09-29 | Harvard College | Universal donor stem cells and related methods |
| AU2020291457B2 (en) * | 2019-06-12 | 2024-11-14 | The Regents Of The University Of California | Engineered off-the-shelf immune cells and methods of use thereof |
| CN114457034A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-1阻断物的多能干细胞衍生物及其应用 |
-
2021
- 2021-12-22 EP EP21854910.3A patent/EP4267723A1/en active Pending
- 2021-12-22 JP JP2023537946A patent/JP2024501246A/ja active Pending
- 2021-12-22 MX MX2023007465A patent/MX2023007465A/es unknown
- 2021-12-22 BR BR112023012432A patent/BR112023012432A2/pt unknown
- 2021-12-22 CA CA3205042A patent/CA3205042A1/en active Pending
- 2021-12-22 IL IL303970A patent/IL303970A/en unknown
- 2021-12-22 AU AU2021410751A patent/AU2021410751A1/en active Pending
- 2021-12-22 KR KR1020237024498A patent/KR20230135068A/ko active Pending
- 2021-12-22 WO PCT/US2021/064933 patent/WO2022140587A1/en not_active Ceased
- 2021-12-22 TW TW110148207A patent/TW202242101A/zh unknown
- 2021-12-22 CR CR20230321A patent/CR20230321A/es unknown
-
2023
- 2023-06-20 CL CL2023001855A patent/CL2023001855A1/es unknown
- 2023-06-22 US US18/339,930 patent/US20240139323A1/en active Pending
- 2023-07-19 CO CONC2023/0009613A patent/CO2023009613A2/es unknown
- 2023-10-17 CL CL2023003089A patent/CL2023003089A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230181698A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| JP7590015B2 (ja) | 低抗原性細胞の製造方法 | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| JP6419107B2 (ja) | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 | |
| JP2024500858A5 (enExample) | ||
| WO2023115732A1 (en) | Single-pot methods for producing circular rnas | |
| JP2022512703A5 (enExample) | ||
| JP2021518160A5 (enExample) | ||
| JP2022524212A (ja) | 操作されたｍＲＮＡ配列及びその使用 | |
| JP2024520528A5 (enExample) | ||
| CN108779465A (zh) | 用于减少pd-l1表达的寡核苷酸 | |
| WO2017075451A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 | |
| JP2021519587A5 (enExample) | ||
| US20250144149A1 (en) | Adenosine deaminase base editors and methods for use thereof | |
| JP2024506016A (ja) | 免疫療法のためのｔ細胞免疫グロブリン及びムチンドメイン３（ｔｉｍ３）組成物及び方法 | |
| CA3179694A1 (en) | Fusion proteins of ctl antigens for treating melanoma | |
| JP2024534639A5 (enExample) | ||
| WO2024148313A2 (en) | Genome editing compositions and methods of use | |
| US20240307444A1 (en) | Methods and compositions for improved immunotherapies | |
| JP2024528967A5 (enExample) | ||
| CN115667288A (zh) | 抗原池 | |
| JP2009536922A (ja) | ウイルスに特異的な可溶性ｔ細胞受容体組成物 | |
| Gim et al. | Identification and expression analyses of equine endogenous retroviruses in horses | |
| RU2025100294A (ru) | Композиции и способы снижения содержания mhc класса i в клетке | |
| EP2570422B1 (en) | Promiscuous HER-2/NEU CD4 T cell epitopes |